Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody combo tested in advanced cancer patients

NCT ID NCT05025085

Disease control Sponsor: Agenus Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new antibody drug called AGEN1777, given alone or with another antibody (a PD-1 inhibitor), in 25 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see how the drug moves through the body. Because it is a phase 1 study, it is too early to know if the drug works well.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AGEN1777 (an antibody) and a PD-1 inhibitor (another antibody)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early phase 1 trial with only 25 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects, and it is far from being proven effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

25 people

The number who actually took part.

Started

Oct 2021

Finished

Apr 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced solid tumor for which no acceptable standard therapy available or progressed on or after standard therapies. 2. Measurable disease on baseline imaging based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). 3. Life expectancy of at least 3 months and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Key Exclusion Criteria: 1. Active infection requiring treatment. 2. Lack of recovery for participants who had major surgical procedure within 4 weeks prior to first dose of protocol therapy. 3. Clinically significant cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months of enrollment, unstable angina, congestive heart failure (New York Heart Association class ≥ II), or serious uncontrolled cardiac arrhythmia requiring medication. 4. Corrected QT interval (QTc) (corrected for heart rate using Fridericia's formula prolongation) \>480 msec at screening except for right bundle branch block.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced cancer

Contacts and locations

Locations

  • Lifespan Cancer Institute

    Providence, Rhode Island, 02903, United States

  • Local Institution - 0001

    Providence, Rhode Island, 02903, United States

  • Local Institution - 024

    Southfield, Michigan, 48075, United States

  • Local Institution - 072

    Cincinnati, Ohio, 45267-0558, United States

  • Local Institution - 164

    Dallas, Texas, 75230, United States

  • Local Institution - 165

    Grand Rapids, Michigan, 49546, United States

  • MD Anderson Cancer Center Thoracic-Head & Neck Med Onc

    Houston, Texas, 77030, United States

  • Mary Crowley Cancer Research

    Dallas, Texas, 75251, United States

  • Providence Cancer Institute

    Portland, Oregon, 97213, United States

  • START Midwest

    Grand Rapids, Michigan, 49546, United States

  • University of Cincinnati Cancer Center

    Cincinnati, Ohio, 45267, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.